EUCTR2005-002984-10-CZ进行中（未招募）1 期
A randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal woman taking calcium and vitamin D
ordic Bioscience0 个研究点目标入组 4,662 人开始时间: 2005年12月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4,662
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •·Postmenopausal, ambulatory women, between 55 and 85 years old
- •·A: BMD T-score <=–2.5 at one or more of the following regions: the lumbar spine, femoral neck or total hip, and no more than 2 prevalent mild or moderate vertebral fractures according to the definition of Genant et al (15). No severe fracture is permitted. The inclusion will be defined by the absolute BMD values (g/cm2).
- •·B: BMD T-score <= –1.5 at one or more of the following regions: the lumbar spine, femoral neck or total hip together with one or two osteoporotic fracture(s) located at the spine according to the definition of Genant et al (15). The inclusion will be defined by the absolute BMD values (g/cm2).
- •·Ethical criteria - before any study-specific procedure is performed, the appropriate written informed consent must be obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Any participant will be excluded from the study, if they have a bone mineral density (BMD) T-score below –4.0 (based on absolute values g/cm2 as given in the protocol) at one or more of the measured sites.
- •·Any participant will be excluded from the study, if they have more than 2 prevalent vertebral fractures (Genant et al, 15).
- •·If BMD is lower than -2.5 T-score at one or more of the measured sites, the participants will be excluded from the study, if they have a severe vertebral fracture (Genant et al, 15).
- •·Participants will be excluded from the study, if they have evidence of any clinical osteoporotic fracture and/or if they have a history of a clinical osteoporotic fracture (excluding wrist fractures). A clinical vertebral fracture is defined as vertebral fracture associated with pain or functional disability.
- •·BMD T-score > -1.5 in all of the following regions: Lumbar spine, femoral neck or total hip.
- •·Evidence of any of the following from medical history, laboratory results, DXA, or X-ray review:
- •oHistory of renal stone
- •oCurrent hyper- or hypothyroidism. Patients on stable thyroid treatment will be allowed
- •oCurrent hyper- or hypoparathyroidism
- •oRheumatoid arthritis
- •oPaget’s disease
- •oMalignancy (except basal cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years
- •oAny bone disease, e.g. osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings
- •oUntreated or symptomatic malabsorption syndrome
- •oHeight, weight and girth which may preclude accurate DXA measurements
- •oAdvanced scoliosis or extensive lumbar fusion which would preclude vertebral fracture assessment
- •oLess than 2 lumbar vertebrae (L1-L4) evaluable for DXA (for the BMD substudy population). Subjects that fulfil the BMD inclusion criteria at the hip, and are not enrolled in the BMD substudy, may be enrolled even if there are not 2 evaluable lumbar vertebrae.
- •oScreening 25 (OH) vitamin D level less than 24 ng/mL (=60 nmol/l). The patient may be treated with 25 (OH) vitamin D3 and serum vitamin D may then be retested.
- •oSerum levels of intact PTH above 68 pg/ml
- •oCurrent hypocalcaemia (albumin adjusted serum calcium below 2.13 mmol/L [8.5 mg/dL])
- •·Any organic or psychiatric disorder, or laboratory abnormality which, in the opinion of the Investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results.
- •·Evidence of alcohol or substance abuse that the Investigator believes would interfere with understanding or completing the study.
- •·Subjects with any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.
- •·The subject is currently enrolled in a clinical study or at least 30 days have not elapsed since ending other investigational device or drug trial(s).
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal woman taking calcium and vitamin DThe trial is Phase III.The population will be healthy post-menopausal women who are between 60 and 85 years of ageEUCTR2005-002984-10-GBordic Bioscience4,500
进行中（未招募）
不适用
A randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal woman taking calcium and vitamin DEUCTR2005-002984-10-DKordic Bioscience4,662
进行中（未招募）
不适用
Clinical study to evaluate the efficacy and safety of diclofenac potassium 25 mg tablets in subjects with acute joint paiankle sprain, grade I - IIMedDRA version: 14.1Level: LLTClassification code 10002549Term: Ankle sprainSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2011-005577-23-DEovartis Consumer Health
进行中（未招募）
不适用
A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acute ankle spraiAnkle sprain, Grade I-IIMedDRA version: 12.1Level: LLTClassification code 10002549Term: Ankle sprainEUCTR2010-020935-38-DEovartis Consumer Health
进行中（未招募）
不适用
A randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal woman taking calcium and vitamin DThe trial is Phase III.The population will be osteoporotic post-menopausal women who are between 55 and 85 years of ageMedDRA version: 9.1Level: LLTClassification code 10031285Term: Osteoporosis postmenopausalEUCTR2005-002984-10-LTordic Bioscience4,662